Is Cardinal (CAH) a Solid Growth Stock? 3 Reasons to Think "Yes"

Zacks' proprietary system recommends Cardinal Health (CAH) as a compelling growth stock, assigning it a Growth Score of 'A' and a Zacks Rank #2. This positive outlook is underpinned by CAH's projected 13.7% EPS growth this year, significantly outpacing the industry average of 7.6%, alongside an impressive asset utilization ratio of 4.61 and anticipated sales growth of 11.4%. Furthermore, the company has seen positive current-year earnings estimate revisions, with the Zacks Consensus Estimate surging 2.8% over the past month, collectively positioning CAH for potential outperformance.

Analysis

Cardinal Health (CAH) presents a compelling growth case based on a convergence of strong fundamental metrics and positive analyst sentiment. The company is projected to deliver earnings per share (EPS) growth of 13.7% this year, a rate that significantly outpaces the 7.6% average expected for its industry. This robust bottom-line expansion is supported by strong top-line momentum, with sales forecast to increase by 11.4%, more than doubling the industry's average growth of 4.6%. Operationally, CAH demonstrates superior efficiency, evidenced by an asset utilization ratio of 4.61, which indicates it generates $4.61 in sales for every dollar of assets—a figure substantially higher than the industry mean of 0.72. Reinforcing this positive outlook, the Zacks Consensus Estimate for current-year earnings has been revised upward by 2.8% over the last month, a historically strong indicator of near-term stock performance. This combination of above-average growth projections, high operational efficiency, and upward estimate revisions underpins the stock's favorable Zacks Rank #2 and 'A' Growth Score.

Key Decisions for Investors

• Given the combination of strong projected EPS growth and superior asset efficiency, growth-focused investors should evaluate Cardinal Health for potential outperformance relative to the broader healthcare distribution sector.
• Investors should closely monitor upcoming quarterly earnings reports to validate that the company's execution is on track to meet the robust sales and earnings growth projections of 11.4% and 13.7%, respectively.
• The 2.8% upward revision in consensus earnings estimates over the past month suggests positive near-term momentum, but positions should be managed with an awareness of the higher volatility typically associated with growth stocks.